Compugen presented a batch of data from early-stage trials of its anti-PVRIG candidate in dual and triple combination studies, including one with an anti-TIGIT therapy, but the pairings are no longer part of the biotech’s […]
Hello, everyone, and how are you today? A steely gray sky is hovering this morning over the Pharmalot campus, where the official mascot is romping about in search of creatures and commuter traffic is humming […]
Avalon Ventures has been a major player in the investing games both in tech and in the biotech world, but now a new fund will be zeroed in on investing in the life science field. […]
Bioregnum Opinion Column by John Carroll Gossamer Bio $GOSS posted a statistically significant improvement for its primary endpoint in the key Phase II TORREY trial for lead drug seralutinib on Tuesday morning. But CEO Faheem […]
NEW YORK & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Pfizer Inc. (NYSE: PFE) and Clear Creek Bio, Inc. today announced a research collaboration and exclusive license agreement to advance the discovery and development of potential inhibitors of the SARS-CoV-2 […]
Pfizer has inked a deal to develop a new Covid therapy with Clear Creek Bio — a 10-person biotech out of RA Capital with an office in Cambridge, MA, but one that operates fully remotely. […]
The Pennsylvania Department of Drug and Alcohol Programs (DDAP) said the funding will aid in alleviating worker shortages and in substance abuse disorder care. Click here to view original post
Pfizer is continuing its run of manufacturing site expansions with two new large investments in the US and Europe. The New York-based pharma giant’s site in Kalamazoo, MI, has seen a lot of attention over […]
The funds were awarded to the institute from the state’s new Angel Investment Venture Capital Program. Click here to view original post
The annual list honors individuals deemed to be the most influential figures in the industry in terms of leadership and impact. Click here to view original post
Copyright © 2022 Biotech Networks, LLC
